Eprimat D Capsule SR is a sustained-release formulation combining Eperisone 150 mg and Diclofenac 100 mg, designed for the management of musculoskeletal conditions characterized by muscle spasm and inflammation. Eperisone acts as a centrally acting muscle relaxant, reducing muscle tone by inhibiting spinal reflexes and improving blood flow to the affected muscles, thereby alleviating stiffness and pain. Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), exerts potent analgesic and anti-inflammatory effects by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), leading to decreased prostaglandin synthesis at the site of inflammation. The combination provides synergistic relief from pain, inflammation, and muscle spasm commonly associated with conditions such as cervical spondylosis, lumbar spondylosis, myofascial pain syndrome, and other soft tissue disorders. The sustained-release formulation ensures prolonged therapeutic action, enhancing patient compliance by reducing dosing frequency. Eprimat D Capsule SR should be used under medical supervision, considering contraindications such as hypersensitivity to NSAIDs, active gastrointestinal ulcers, severe hepatic or renal impairment, and caution in patients with cardiovascular risk factors. Common adverse effects may include gastrointestinal discomfort, dizziness, and allergic reactions. Appropriate monitoring is advised during prolonged therapy to ensure safety and efficacy.